Seongnam--(뉴스와이어)--3D bioprinting company CLECELL announced that it had signed an MoU with Taiwanese bio company CancerFree Biotech for the commercialization of an organoid-based anti-cancer drug sensitivity test.

Since its establishment in 2016, CLECELL had been exploring various applications leveraging its differentiated 3D bioprinting technology. Anti-cancer drug sensitivity test, the evaluation of the degree to which cancer cells respond to anti-cancer drugs, is one of the areas that the company has investigated.

CancerFree Biotech, founded in Taiwan, has developed in vitro platform which tests the sensitivity of anti-cancer drugs by extracting a small amount of circulating tumor cells from the blood and culturing them to create a 3D organoid model. Based on this platform, the business tested the efficacy of anti-cancer medications on more than 1,000 patients along with 100 varieties of solid tumor cancer cells in Asia.

CLECELL has planned to integrate the sensitivity evaluation technology of CancerFree with its product development and therefore provide medical facilities with better services. Additionally, the two companies will work together to develop a more sensitive evaluation model of cancer cells from patients and enter the global market afterward.

The size of the cancer treatment market, worth $187 billion in 2021, and in vitro diagnostics, which exceeds 99 billion, made anti-cancer drug sensitivity services a promising market. “Anti-cancer drug sensitivity test is a field worthwhile to challenge not only as a profit model for the company but also as a mission to contribute to humanity by increasing the survival ratio of cancer patients through an accurate selection of anti-cancer drugs. In order to shorten the research and development period and build up an effective service model to test anti-cancer drugs, we are trying to cooperate with the 3rd parties in Korea as well as the global market,” said Kyoung Whee Jeon, the CEO of CLECELL.